Mediclinic International have declared an interim dividend per share that is maintained at 3.20 pence (1H19: 3.20 pence), with the Group applying its full-year dividend policy of 25% to 35% of adjusted earnings per share.
Other financial highlights include:
Revenue up 9% to £1 515m; up 6% in constant currency, reflecting growth across all three divisions
Adjusted EBITDA up 4% at £222m; up 3% in constant currency terms, reflecting adjusted EBITDA margins in line with expectations for all three divisions
Adjusted operating profit flat at £137m, reflecting increased depreciation charges associated with infrastructure and technology investments; reported operating profit up 264% to £142m, reflecting prior year period non-cash Hirslanden impairment charges of £98m
Reported earnings of £112m (1H19: loss of £168m), reflecting prior year period non-cash impairment charges on the equity investment in Spire of £164m
Net debt at £1 775m reflects borrowings incurred; leverage ratio flat on FY19 at 3.5x
Adjusted earnings per share flat at 10.3 pence
Improved cash conversion at 98% of adjusted EBITDA (1H19: 69%)
